Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
ViewRay® to Present at the 2018 Cantor Global Healthcare Conference
ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to present at the Cantor Global Healthcare Conference in New York, NY on Tuesday, October 2, 2018.
Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay’s MRIdian® Linac. These treatments mark the first in Turkey using MRI-guided radiation therapy.
ViewRay Announces Pricing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY) announced the pricing of an underwritten public offering of 16,216,217 shares of common stock at a price to the public of $9.25 per share, for gross proceeds of $150 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy